Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis

BACKGROUND: There is limited guidance on which biologic therapies should be prioritised for the treatment of moderate-to-severe psoriasis, amongst the many available options. New mode-of-action biologics, as well as recently available biosimilars for existing biologics, continue to be developed maki...

Descripción completa

Detalles Bibliográficos
Autores principales: Barker, Jonathan, Baker, Hannah, Nadeem, Ayeda, Gu, Dong-Ha, Girolomoni, Giampiero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556196/
https://www.ncbi.nlm.nih.gov/pubmed/34655022
http://dx.doi.org/10.1007/s40261-021-01089-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556196/
https://www.ncbi.nlm.nih.gov/pubmed/34655022
http://dx.doi.org/10.1007/s40261-021-01089-4

Ejemplares similares